Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2024

Description

“Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for exocrine pancreatic insufficiency (epi) therapeutics and diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Therapies: Nutritional Management; Pancreatic Enzyme Replacement Therapy (PERT); Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests; Magnetic Resonance Imaging (MRI); Endoscopic Ultra-Sonography (EUS); Computerized Tomography (CT) Scanning
3) By Drug Type: Generic; Branded
4) By Distribution Channel: Direct Tender; Retail Pharmacy ; Third-Party Distributor; Other Distribution Channels
5) By End User: Hospitals; Specialty Clinics; Homecare; Diagnostic Center; Research And Academic Institutes; Other End Users
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Janssen Pharmaceuticals Inc.; AbbVie Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics pertain to the treatment of a condition where the pancreas fails to produce adequate digestive enzymes necessary for the effective breakdown and absorption of nutrients from food within the small intestine. The role of EPI diagnostics and therapeutics is pivotal in the identification and management of exocrine pancreatic insufficiency, facilitating individuals with EPI in attaining improved nutrient absorption and overall well-being.

The primary forms of treatments encompassed within exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics comprise nutritional management, pancreatic enzyme replacement therapy (PERT), and lifestyle adjustments. Nutritional management is a specialized healthcare approach utilizing nutrition and diet to address various medical and health conditions. Diverse diagnostic techniques are employed, including blood tests, magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), and computerized tomography (CT) scanning. Various types of medications, both generic and branded, are utilized, and these are distributed through a range of channels such as direct tender, retail pharmacy, third-party distributor, and others. These are availed by a diverse array of end users including hospitals, specialty clinics, homecare, diagnostic centers, research and academic institutes, among others.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report is one of a series of new reports from The Business Research Company that provides exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market statistics, including exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market share, detailed exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market segments, market trends and opportunities and any further data you may need to thrive in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry. This exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size has grown strongly in recent years. It will grow from $5.24 billion in 2023 to $5.69 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, rising global healthcare access.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size is expected to see strong growth in the next few years. It will grow to $7.67 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.

The surge in diabetes cases is anticipated to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the foreseeable future. Diabetes is a persistent metabolic ailment characterized by prolonged elevated blood sugar levels (hyperglycemia) resulting from either insufficient insulin production or the body's inefficiency in using the insulin it generates. EPI treatment, which encompasses pancreatic enzyme replacement therapy (PERT), proves beneficial in enhancing nutrient absorption for individuals with both diabetes and EPI. Moreover, it aids in bettering glycemic control for those with diabetes. For instance, as of November 2021, the International Diabetes Federation, a Belgium-based conglomerate of over 230 national diabetes associations, reported that an estimated 537 million adults (20-79 years old) were afflicted with diabetes in 2021. Furthermore, the total number of individuals grappling with diabetes is projected to escalate to 643 million by 2030 and 783 million by 2045. Consequently, the mounting prevalence of diabetes is a key driver for the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market's growth.

The surge in cases of gastrointestinal disorders is projected to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the foreseeable future. Gastrointestinal disorders encompass a range of medical conditions affecting the digestive tract, including the organs responsible for digestion. Managing gastrointestinal diseases relies significantly on exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics, which rectify enzyme deficiencies and promote effective nutrient digestion. For instance, as of June 2023, Crohn's and Colitis Canada, a non-profit organization based in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting about 0.82% of the population. With the prevalence of IBD projected to persist, it is anticipated that approximately 470,000 Canadians will have IBD by 2035, roughly 1.1% of the population, or about 1 in every 91 individuals in the country. Consequently, the escalating incidence of gastrointestinal disorders is anticipated to be a driving force behind the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

The exorbitant cost of treatment is anticipated to hinder the progress of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market throughout the forecast period. High treatment expenses in healthcare refer to the substantial financial outlays associated with medical care, often posing a considerable burden on individuals. The treatment modalities for exocrine pancreatic insufficiency (EPI) encompass nutritional management and pancreatic enzyme replacement therapy (PERT), which can be either generic or branded, leading to moderate to high costs incurred during the treatment process. As an illustration, in January 2021, as reported by the American Society of Clinical Oncology, a US-based professional organization representing physicians across all oncology sub-specialties, the out-of-pocket expenses for a 30-day supply of enzymes for Medicare beneficiaries could reach up to $1000. The lipase content per unit spanned from 3,000 to 40,000 USP units, with a per-unit list price ranging from $1.44 to $13.89. Consequently, the elevated treatment costs served as a significant constraint on the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

Prominent companies in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are dedicated to pioneering innovative studies and solutions, like PACT-CP, to maintain their standing in the industry. For instance, in June 2021, Aimmune Therapeutics, a biopharmaceutical company based in the United States, introduced PACT-CP-a patient-centric chronic pancreatitis registry study. This initiative aims to gain deeper insights into the unmet needs and therapeutic challenges faced by patients dealing with EPI as a consequence of chronic pancreatitis (CP). Notably, it stands as the inaugural real-world registry study designed specifically for individuals with chronic pancreatitis. The study, which will track approximately 400 patients across 20 gastroenterology facilities in the United States, was developed in collaboration with patients and expert advisors. The PACT-CP Registry study constitutes a forward-looking, non-interventional research endeavor tailored for patients undergoing gastroenterology treatment and diagnosed with EPI stemming from chronic pancreatitis.

In September 2021, AzurRx BioPharma, a clinical-stage biopharmaceutical company headquartered in the United States, completed the acquisition of First Wave Bio Inc. for a total of $229 million. This pivotal acquisition has led AzurRx to rebrand as 'First Wave BioPharma Inc.' The strategic move signifies a significant expansion of the company's gastrointestinal (GI) development portfolio, propelling AzurRx into a prominent position in the realm of therapeutic interventions for inflammatory bowel diseases. First Wave Bio Inc., a US-based pharmaceutical entity, specializes in treating exocrine pancreatic insufficiency (EPI) in patients afflicted with cystic fibrosis and chronic pancreatitis.

Major players in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, Abott Laboratories, Medtronic plc, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan plc, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG .

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2023. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market consists of revenues earned by entities by providing dietary interventions and bile acid replacement therapy (BAR). The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market also includes sales of Creon, Zenpep and Ultresa. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12338

1. Executive Summary

2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Characteristics

3. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends And Strategies

4. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size and Growth

5.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segmentation

6.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Nutritional Management
Pancreatic Enzyme Replacement Therapy (PERT)
Lifestyle Modifications Approach
6.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Blood Tests
Magnetic Resonance Imaging (MRI)
Endoscopic Ultra-Sonography (EUS)
Computerized Tomography (CT) Scanning
6.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Generic
Branded
6.4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Direct Tender
Retail Pharmacy
Third-Party Distributor
Other Distribution Channels
6.5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Specialty Clinics
Homecare
Diagnostic Centre
Research And Academic Institutes
Other End Users

7. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Regional And Country Analysis

7.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

8.1. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

9.1. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
9.2. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

10.1. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

11.1. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
11.2. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

12.1. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

13.1. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

14.1. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
14.2. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

15.1. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
15.2. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

16.1. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

17.1. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

18.1. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

19.1. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

20.1. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

21.1. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
21.2. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

22.1. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

23.1. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
23.2. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

24.1. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
24.2. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

25.1. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
25.2. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

26.1. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
26.2. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

27.1. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

28.1. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
28.2. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

29.1. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
29.2. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Landscape And Company Profiles

30.1. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Landscape
30.2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Merck & Co. Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Janssen Pharmaceuticals Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AbbVie Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. AstraZeneca plc
31.3. Abott Laboratories
31.4. Medtronic plc
31.5. Solvay S.A.
31.6. Laboratory Corporation of America Holdings (Labcorp)
31.7. Organon group of companies Metagenics LLC
31.8. Allergan plc
31.9. Chiesi Farmaceutici S.p.A.
31.10. Codexis Inc.
31.11. Nordmark Arzneimittel GmbH & Co. KG
31.12. ChiRhoClin Inc.
31.13. Digestive Care Inc.
31.14. Alcresta Therapeutics Inc.
31.15. Vivus Inc.

32. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Benchmarking

33. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

35. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Future Outlook and Potential Analysis

35.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2028 - Countries Offering Most New Opportunities
35.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2028 - Segments Offering Most New Opportunities
35.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer